Cancers 2010, 2, 1-19; doi:10.3390/cancers2010001

Review

Novel Combinations for the Treatment of Metastatic Breast Cancer

Linda T. Vahdat

Weill Cornell Medical College, 425 East 61st Street, 8th Floor, New York, NY 10065, USA; E-Mail: ltv2001@med.cornell.edu; Tel.: +1-212-821-0644; Fax: +1-212-821-0758

Received: 17 November 2009; in revised form: 29 December 2009 / Accepted: 5 January 2010 / Published: 14 January 2010

Abstract: Anthracyclines and taxanes represent the mainstay of first-line cytotoxic therapy for metastatic breast cancer (MBC), but most patients eventually develop resistance to these agents. Consequently, alternative combinations for MBC therapy are the subject of much ongoing research. Capecitabine and ixabepilone is the only chemotherapy combination specifically approved for MBC after failure of anthracyclines and taxanes. Other options have limited data to support their use in this setting but are commonly used in practice. Future MBC therapies will likely combine alternative chemotherapies and novel biologic agents, and numerous ongoing trials should help to further define the proper use of these regimens.

Keywords: metastatic breast cancer; anthracycline failure; taxane failure; combination therapy; chemotherapy; targeted or biologic therapy; outcomes; survival

1. Introduction

Breast cancer accounts for 26% of all diagnosed female cancers in the United States, and is the second most common cause of cancer mortality. Approximately 182,460 new cases and 40,480 deaths were anticipated in 2008 [1]. Only a small minority will have metastatic breast cancer (MBC) at the time of presentation (approximately 6%), but recurrence rates vary from 20% to 60% depending on molecular subtype, tumor size, and nodal status [2,3]. Despite therapeutic advances in recent years, prognosis remains poor for MBC, with a median survival of up to 4 years [4] and a 5-year survival rate of approximately 27% [2].
Treatment for MBC is rarely curative, so palliating symptoms, prolonging survival, and maintaining/improving quality of life are usually the main treatment goals. Less toxic therapies are therefore preferred, if possible. As the median age of breast cancer patients is 65 years, a substantial proportion of older patients may not tolerate highly aggressive therapy because of associated toxicity. There is currently no gold standard regimen for MBC, and treatment guidelines recommend several alternatives (Table 1) [5]. Improved survival in a randomized controlled trial is the standard requirement for drug approval first-line, but time-to-progression (TTP) and progression-free survival (PFS) have supported second- and third-line approvals [6].

**Table 1. Preferred chemotherapy agents and regimens for MBC [5].**

| Single agents                                                                 |
|--------------------------------------------------------------------------------|
| Doxorubicin, epirubicin; pegylated liposomal doxorubicin, paclitaxel, docetaxel, nab-paclitaxel, capecitabine, vinorelbine, gemcitabine |

| Combination chemotherapy                                          |
|------------------------------------------------------------------|
| CAF/FAC; FEC; AC; EC; AT; CMF; docetaxel + capecitabine; gemcitabine + docetaxel |

| Combinations with molecular targeted therapies                        |
|------------------------------------------------------------------|
| Trastuzumab – first-line, HER2-positive disease                   |
| Trastuzumab + paclitaxel ± carboplatin                            |
| Trastuzumab + docetaxel                                           |
| Trastuzumab + vinorelbine                                         |
| Trastuzumab + capecitabine                                        |
| Trastuzumab-exposed, HER2-positive disease                        |
| Lapatinib + capecitabine                                          |
| Trastuzumab + other first-line agents                             |
| Trastuzumab + capecitabine                                        |
| Trastuzumab + lapatinib                                           |
| Bevacizumab – first-line, HER2-negative disease                   |
| Bevacizumab + paclitaxel                                          |

| Other active options                                              |
|------------------------------------------------------------------|
| Cyclophosphamide, mitoxantrone, cisplatin; oral etoposide, vinblastine, fluorouracil continuous infusion; ixabepilone, capecitabine + ixabepilone |

Abbreviations: AC, doxorubicin/cyclophosphamide; AT, doxorubicin + docetaxel or paclitaxel; CAF/FAC, cyclophosphamide, doxorubicin + fluorouracil; CMF, cyclophosphamide, methotrexate, fluorouracil; EC, epirubicin + cyclophosphamide; FEC, fluorouracil, epirubicin + cyclophosphamide.

Predominant factors affecting treatment choice include patient characteristics, such as age, menopausal status, and personal preference, and tumor and disease characteristics, such as site and extent of disease, tumor hormone receptor status, level of human epidermal growth factor receptor 2 (HER2) expression, prior treatment exposure, and disease-free interval [5].

Cytotoxic chemotherapies approved for MBC are myriad and include the anthracyclines (doxorubicin, epirubicin, and liposomal doxorubicin), the taxanes (paclitaxel, nab-paclitaxel, and docetaxel), capecitabine, gemcitabine, and an epothilone, ixabepilone. Additional active agents include cyclophosphamide, mitoxantrone, cisplatin, oral etoposide, vinorelbine, vinblastine, and 5-fluorouracil. Another agent showing promise for MBC is E7389 (eribulin), a synthetic analog of halichondrin B.
(HB) and nontaxane microtubule dynamics inhibitor, shown to have highly potent anticancer activity in vitro and in vivo [7]. In a phase II trial of patients with refractory breast cancer who had received 2–5 prior chemotherapy regimens and progressed on or within six months of their last chemotherapy (N = 269 for efficacy population), the overall response rate (ORR) with eribulin was 14% according to investigator assessment (IA) [8]. A phase III study of eribulin versus the physician’s treatment choice is underway in locally recurrent or MBC. Patients are eligible if previously treated with ≥2 and ≤5 prior chemotherapy regimens, including an anthracycline and taxane.

2. First-line Therapy

Paclitaxel and docetaxel are microtubule stabilizers and among the most active agents in MBC. They are widely used in sequence or combination with an anthracycline first-line for locally-advanced disease or MBC. A recent meta-analysis, including trial data from >4,000 patients, showed increased ORRs and prolonged PFS with taxane regimens, but not prolonged overall survival (OS) versus nontaxane regimens [9]. Gemcitabine combined with paclitaxel is another approved first-line option for MBC, after failure of prior anthracycline-containing adjuvant chemotherapy [5]. Approval was based on a phase III trial of 529 patients, in which this combination produced higher ORRs (41% vs. 26%, P = 0.0002), a longer median TTP (6.1 months vs. 4.0 months, P = 0.0002), and a longer OS (18.6 months vs. 15.8 months, P = 0.049) than paclitaxel alone [10].

The first-line combination of gemcitabine plus nab-paclitaxel was recently evaluated in a phase II trial (n = 50). Nab-paclitaxel (125 mg/m²) plus gemcitabine (1,000 mg/m²) led to an ORR of 50%, and the median duration of response was 6.9 months. Median PFS was 7.9 months, but median OS was not reached. Therapy was well tolerated; neutropenia was the most common adverse event (grade 3, 43%; grade 4, 12%) [11].

Biologic targeted therapies are a major aspect of the treatment spectrum for MBC and have further improved prognosis. Trastuzumab, which targets HER2, may be used as monotherapy or combined with chemotherapies including paclitaxel, docetaxel, vinorelbine, or capecitabine for HER2-positive MBC [5]. Results from a recent randomized phase III trial found that immediate combination therapy with trastuzumab (4 mg/kg loading dose, followed by 2 mg/kg weekly) and docetaxel (60 mg/m²) was superior to sequential single-agent trastuzumab followed by the trastuzumab and docetaxel doublet after disease progression in terms of both PFS (HR, 4.24; P = 0.01) and OS (HR, 2.72; P = 0.04) [12]. While trastuzumab therapy is appropriate only for HER2-positive MBC, combining the antivasular endothelial growth factor (VEGF) monoclonal antibody bevacizumab and paclitaxel offers a first-line regimen for HER2-negative MBC [5,13]. Activity of bevacizumab is not limited to HER2-negative disease, however, as the combination of bevacizumab and trastuzumab appears to be active and well tolerated as first-line therapy for patients with HER2-positive disease (clinical benefit rate, 60%) [14]. Recent data from the RIBBON-2 trial suggest that bevacizumab combinations may also be useful beyond first-line therapy, as discussed in a subsequent section [15].
Established salvage cytotoxic agents frequently used after anthracyclines and taxanes include capecitabine, vinorelbine, gemcitabine, platinum salts, liposomal doxorubicin, and ixabepilone. Capecitabine and ixabepilone are the only chemotherapy agents approved for MBC after failure of anthracycline and taxane therapy [5]. Capecitabine monotherapy (1,250 mg/m$^2$ twice daily for two weeks, in 3-week cycles) is approved for patients whose tumors are resistant to paclitaxel and an anthracycline, or paclitaxel alone where an anthracycline is contraindicated. In two randomized, phase II studies, capecitabine achieved ORRs in 20% to 27% of patients, with a median survival of approximately 1 year [16,17]. Capecitabine plus docetaxel (75 mg/m$^2$ every three weeks) is indicated after prior anthracycline therapy on the basis of phase III trial results [18]. In addition, capecitabine is approved as salvage therapy in combination with the HER2-targeted agent lapatinib, in HER2-positive, taxane- and trastuzumab-pretreated disease.

Ixabepilone is a microtubule inhibitor has a distinct mode of action to the taxanes and low susceptibility to tumor resistance mechanisms [19–21]. Ixabepilone is the first epothilone approved by the Food and Drug Administration (FDA) for locally-advanced or MBC, either as monotherapy following progression on an anthracycline, a taxane, and capecitabine, or combined with capecitabine following anthracycline and taxane failure.

The clinical activity of ixabepilone monotherapy was shown in a phase II trial of 126 patients resistant to an anthracycline, a taxane, and capecitabine, with 88% receiving at least two lines of prior chemotherapy for MBC [22]. Single-agent ixabepilone produced ORRs in 12% of patients by independent radiology review (IRR), and 50% of patients achieved stable disease. The median duration of response was 5.7 months, and median PFS was 3.1 months. In 65 patients with MBC pretreated with an adjuvant anthracycline only, ixabepilone monotherapy 40 mg/m$^2$ every three weeks led to an ORR of 42%, a median duration of response of 8.2 months and median OS of 22.0 months [23].

In a subsequent phase III trial of 752 patients, almost all (97%) had anthracycline- and/or taxane-resistant MBC. Anthracycline resistance was defined as disease recurrence occurring while on therapy or within 6 months of completing adjuvant or neoadjuvant therapy, or within three months of the last dose for MBC. Taxane resistance included progression while on therapy or within 12 months of the last dose in the adjuvant setting, or within 4 months in the metastatic setting. Capecitabine plus ixabepilone achieved an ORR of 35% versus 14% with capecitabine alone, according to IRR ($P < 0.0001$) [24,25]. The ORR by IA was 42% versus 23%, respectively. Median PFS was 5.7 months versus 4.1 months by IRR ($P < 0.0001$; 31% reduction in the risk of disease progression), and 5.3 months versus 3.3 months by IA ($P = 0.0011$, 22% risk reduction) [24–26]. These results of the pivotal trial are supported by a confirmatory phase III study of patients pretreated with an anthracycline and/or taxane (approximately 50% were resistant to taxanes) [26]. A subsequent pooled analysis of patients with taxane-resistant tumors in both trials showed an ORR rate of 39% with ixabepilone plus capecitabine versus 22% with capecitabine alone, a median PFS of 5.1 months versus 3.7 months and a median OS of 13.3 months versus 11.6 months, respectively [27].

Treatment options are particularly limited for patients with triple negative or basal-like MBC resistant to taxanes and/or anthracyclines [28], but ixabepilone plus capecitabine has shown efficacy in these patients. In a pooled subgroup analysis of the phase III trials [24,26], capecitabine plus...
ixabepilone achieved an ORR of 31% in 191 patients with triple-negative tumors (vs. 15% in 208 patients treated with capcitabine alone), and a median PFS of 4.2 months (vs. 1.7 months with capcitabine alone) [29]. Subgroup analyses of HER2-positive or ER-negative patients have shown that this combination is associated with higher ORRs than capcitabine monotherapy [30,31]. Ixabepilone also yielded clinical benefit in two other challenging subgroups of MBC: patients that relapse within 1 year of completing adjuvant anthracycline/taxane therapy [32] and symptomatic patients (Karnofsky performance status 70–80) [33].

A randomized phase III adjuvant trial sponsored by the Sarah Cannon Research Institute and Bristol-Myers Squibb (TITAN; NCT00789581) is currently enrolling patients with triple-negative breast cancer. Patients will receive doxorubicin plus cyclophosphamide followed by ixabepilone versus paclitaxel (TITAN). A second phase III adjuvant trial (PACS 08; NCT00630032) is examining the role of sequential 5-fluorouracil, epirubicin, and cyclophosphamide (FEC-100), and ixabepilone (vs. FEC-100 and docetaxel) for triple-negative breast cancer. The planned accrual is 2,500 patients.

Various novel chemotherapy combinations and head-to-head studies with ixabepilone are under investigation. A phase II trial (IXTEND) is recruiting to compare ixabepilone plus capcitabine with docetaxel plus capcitabine in MBC (NCT00546364; www.clinicaltrials.gov). Ongoing phase II studies of patients with MBC also are evaluating ixabepilone in combination with liposomal doxorubicin and carboplatin. Preliminary data from a phase Ib study indicate that the combination of ixabepilone with epirubicin has a favorable toxicity and efficacy profile [34]. This study has now been completed.

**Novel Chemotherapy and Targeted Agent Combinations**

The future of MBC therapy will focus on combinations incorporating effective chemotherapy and novel biologics. This approach has yielded notable success with the HER2-targeted agents trastuzumab and lapatinib, and some success with the angiogenesis inhibitor bevacizumab. All of these agents have improved TTP and/or PFS compared with chemotherapy alone in patients with MBC. Several trials are evaluating combinations of these drugs and other targeted therapies with chemotherapy in the first-line MBC setting. Phase III trial results are summarized in Table 2 [13,35–44].

**4. Bevacizumab Combinations**

In the pivotal, first-line, phase III study in HER2-negative MBC, adding bevacizumab 10 mg/kg to paclitaxel 90 mg/m$^2$ significantly increased the ORR (37% vs. 21%, $P < 0.001$) and PFS (11.8 months vs. 5.9 months; $P < 0.001$) but OS was similar in both treatment groups [13]. Clinical experience has suggested that bevacizumab plus nab-paclitaxel is effective and well tolerated as a first-line MBC therapy (Link et al. [45]: retrospective analysis of 40 women; Lobo et al. [46]: single institution experience of six patients receiving bi-weekly nab-paclitaxel 100 mg/m$^2$ plus bevacizumab 10 mg/kg, three patients also received gemcitabine 1,000 mg/m$^2$). Early results from a phase II trial showed a 91% ORR (10/11 patients) with bevacizumab 10 mg/kg plus gemcitabine 1,500 mg/m$^2$ and nab-paclitaxel 150 mg/m$^2$, administered on days 1 and 15 of 28-day cycles [47].
Table 2. Summary of phase III clinical trials combining chemotherapy and targeted biologic therapy for the first-line treatment of MBC.

| Reference                  | Chemotherapy                        | N   | ORR (% | TTP (months) | PFS (months) | OS (months) |
|----------------------------|--------------------------------------|-----|--------|--------------|--------------|-------------|
| **Bevacizumab combinations** |                                      |     |        |              |              |             |
| Miller et al. 2007 [13]    | Paclitaxel + bevacizumab             | 368 | 37     | 11.8         | 26.7         |             |
|                            | Paclitaxel                           | 354 | 21     | 5.9          |              | 25.2        |
| Miles et al. 2008 [35]     | Docetaxel + bevacizumab (7.5 mg/kg)  | 248 | 55     |              |              |             |
|                            | Docetaxel + bevacizumab (15 mg/kg)   | 247 | 63     |              |              |             |
|                            | Docetaxel                            | 241 | 44     |              |              |             |
| Miller et al. 2005 [36]    | Capecitabine + bevacizumab           | 232 | 20     | 4.9          | 15.1         |             |
|                            | Capecitabine                         | 230 | 9      | 4.2          | 14.5         |             |
| Robert et al. 2009 [37]    | Capecitabine + bevacizumab           | 409 | 35     | 8.6          | 29.0         |             |
|                            | Capecitabine                         | 206 | 24     | 5.7          | 21.2         |             |
|                            | Taxane/anthracycline + bevacizumab   | 415 | 51     | 9.2          | 25.2         |             |
|                            | Taxane/anthracycline                 | 207 | 38     | 8.0          | 23.8         |             |
| **Trastuzumab combinations** |                                      |     |        |              |              |             |
| Slamon et al. 2001 [38]    | Paclitaxel + trastuzumab             | 92  | 41     | 6.9          | 22.1         |             |
|                            | Paclitaxel                           | 96  | 17     | 3.0          | 18.4         |             |
| Robert et al. 2006 [39]    | Paclitaxel + carboplatin + trastuzumab | 98  | 52     | 10.7         | 35.7         |             |
|                            | Paclitaxel + trastuzumab             | 98  | 36     | 7.1          | 32.2         |             |
| Pegram et al. 2007 [40]    | Docetaxel + carboplatin + trastuzumab | 131 | 73     | 10.4         | 36.6         |             |
|                            | Docetaxel + trastuzumab              | 131 | 73     | 11.1         | 36.4         |             |
| Von Minckwitz et al. 2008  | Capecitabine + trastuzumab           | 78  | 49     | 8.5          | 20.3         |             |
|                            | Capecitabine                         | 78  | 25     | 5.6          | 19.9         |             |
| **Lapatinib combinations** |                                      |     |        |              |              |             |
| Cameron et al. 2008 [42]   | Capecitabine + lapatinib             | 198 | 24     | 6.2          | 15.6         |             |
|                            | Capecitabine                         | 201 | 14     | 4.3          | 15.3         |             |
| Di Leo et al. 2008 [43]    | Paclitaxel + lapatinib               | 291 | 35     | 29.0 weeks   | 99.1 weeks   |             |
|                            | Paclitaxel                           | 288 | 25     | 22.9 weeks   | 87.0 weeks   |             |
| **Trastuzumab and lapatinib combination** |                |     |        |              |              |             |
| O'Shaughnessy et al. 2008  | Trastuzumab + lapatinib              | 148 | 10     | 3 (12 weeks) | 51.6         |             |
|                            | Lapatinib                            | 148 | 7      | 2 (8.4 weeks) | 39.0         |             |
Adding bevacizumab to docetaxel first-line significantly improved clinical outcomes in MBC in the phase III AVADO trial [35], although gains were modest for TTP. Preliminary data showed an increased ORR with bevacizumab 7.5 mg/kg or 15 mg/kg combined with docetaxel 100 mg/m² every three weeks (55% and 63% compared with 44% for single-agent docetaxel). The stratified hazard ratio (HR) for PFS was reduced with the addition of bevacizumab at both doses compared with docetaxel alone (0.69 and 0.61 for bevacizumab 7.5 mg/kg and 15 mg/kg, respectively). OS data has not been reported. A phase III trial will evaluate adding bevacizumab to docetaxel and trastuzumab in first-line, HER2-positive MBC (NCT00391092).

In a phase III trial of patients with heavily-pretreated MBC, capecitabine 2,500 mg/m²/day on days 1 to 14 every three weeks, plus bevacizumab 15 mg/kg on day 1, significantly increased the ORR (20% vs. 9%; \( P = 0.001 \)), but not PFS (4.9 months vs. 4.2 months), or OS (15.1 months vs. 14.5 months) [36]. A single-arm, phase II study of capecitabine plus bevacizumab in 106 patients with chemo-naïve MBC reported an ORR of 38% [48]. A phase III trial will compare capecitabine and paclitaxel, both combined with bevacizumab, as first-line treatment for MBC (NCT00600340, not yet recruiting).

Two ongoing phase III RIBBON trials further elucidated the role of bevacizumab combinations. Results of RIBBON 1, which combined bevacizumab with chemotherapy in previously-untreated MBC (NCT00262067), provided confirmation that incorporating bevacizumab 15 mg/kg into 28-day chemotherapy regimens with a taxane (nab-paclitaxel 260 mg/m² or docetaxel 75 or 100 mg/m² on day 1), capecitabine-(2,000 mg/m²/day on days 1 to 14), or anthracycline-based therapy (day 1) significantly improved PFS over chemotherapy alone (Table 2) [37]. The RIBBON 2 trial combined bevacizumab with chemotherapy (docetaxel, gemcitabine, or vinorelbine) in previously-treated MBC and, in contrast to the previous study reported above, identified a significant improvement in PFS over chemotherapy alone (7.2 months vs. 5.1 months) [15]. The upcoming RIBBON-3 trial will explore the efficacy of continuing bevacizumab through multiple lines of chemotherapy.

Irinotecan, a topoisomerase I inhibitor, was originally reported to be of limited utility for salvage therapy of breast cancer [49], but is currently being re-evaluated in this setting in phase II trials. One of these adds bevacizumab to twice-weekly irinotecan in patients with MBC and brain metastases (NCT00476827).

5. Trastuzumab Combinations

Current guideline-preferred cytotoxics for combination with trastuzumab include paclitaxel, both with and without carboplatin (FDA approved), docetaxel, and vinorelbine (Table 1). In a phase III trial, adding a loading dose of 4 mg/kg trastuzumab, followed by a weekly 2 mg/kg dose, to 3-weekly paclitaxel (175 mg/m²) first-line for HER2-positive, locally-advanced, or MBC prolonged TTP (6.9 months compared with 3.0 months for paclitaxel alone, \( P < 0.001 \)) [38]. In a subsequent phase II study, adding trastuzumab to weekly paclitaxel prolonged TTP (301 days vs. 204 days for paclitaxel alone) [50]. Similarly, adding trastuzumab to docetaxel in a phase II trial first-line significantly improved TTP compared with docetaxel alone (11.7 months vs. 6.1 months) [51].

Chemotherapy doublets with trastuzumab first-line have also been evaluated. A phase III trial comparing trastuzumab 4 mg/kg loading dose plus 2 mg/kg weekly and paclitaxel 175 mg/m² every three weeks, with trastuzumab plus paclitaxel at the same doses combined with carboplatin area-under-
the-curve (AUC) 6 every three weeks. The ORR was 36% versus 52% ($P = 0.04$), respectively, with a median PFS of 7.1 and 10.7 months ($P = 0.03$). OS was similar between groups at 32.2 and 35.7 months ($P = 0.76$) [39]. Results from the phase III BCIRG 007 trial were reported at The American Society of Clinical Oncology (ASCO) Annual Meeting in 2007 [40], showing that trastuzumab (4 mg/kg loading dose, 2 mg/kg weekly, then 6 mg/kg 3-weekly) combined with docetaxel (100 mg/m$^2$) and carboplatin (AUC 6), or trastuzumab plus docetaxel without carboplatin were highly effective as first-line therapy for HER2-positive MBC, achieving median OS times in excess of 36 months. There was no significant difference between arms in median TTP (10.4 months vs. 11.1 months respectively, $P = 0.57$) or ORR (73% in both arms). These combinations are being evaluated first-line in an ongoing phase III trial (NCT00047255).

Many other chemotherapy agents are being combined with trastuzumab in phase III trials. For example, a phase III trial is planned to compare docetaxel and vinorelbine, both in combination with trastuzumab, in chemo-naive patients with HER2-positive MBC (recruiting at present; NCT00430001). Trastuzumab plus capecitabine is being assessed in patients with MBC progressing during trastuzumab therapy [41]. Preliminary results indicate that continuing trastuzumab after progression and adding capecitabine is more effective than second-line capecitabine alone (PFS 8.5 months with 48 events vs. 5.6 months with 53 events). In another ongoing phase III trial (NCT00440622), capecitabine and gemcitabine, both combined with trastuzumab, are being compared in patients with pretreated MBC. Trastuzumab plus the semisynthetic taxane, larotaxel, is currently undergoing phase II evaluation in MBC (NCT00387907).

Combining trastuzumab with other targeted agents may also have promise in MBC. For example, a phase II trial is examining trastuzumab plus lapatinib as first-, second-, or third-line therapy for HER2-positive disease (NCT00470704). A phase II study has already shown that trastuzumab as a 4 mg/kg loading dose followed by 2 mg/kg/weekly, or an 8 mg/kg loading dose followed by 6 mg/kg/3-weekly, plus a pertuzumab 840 mg loading dose followed by 420 mg 3-weekly, produced an ORR of 24% (16/66 patients), with 50% of patients achieving clinical benefit (including stable disease) [52]. A phase III first-line MBC trial of this regimen is due to complete in 2012 (CLEOPATRA; NCT00567190).

6. Lapatinib Combinations

A novel treatment regimen that has recently been approved by the FDA is capecitabine plus lapatinib, for HER2-positive MBC following prior anthracyclines, taxanes, and trastuzumab. Approval was based on a phase III trial of heavily pretreated and trastuzumab-refractory patients ($N = 399$). Adding lapatinib 1,250 mg/day to capecitabine 2,000 mg/m$^2$ on days 1 to 14 of a 21-day cycle increased median TTP from 4.3 months to 6.2 months ($P < 0.001$), with a trend toward improved OS (15.6 months vs. 15.3 months; HR: 0.78, 95% confidence interval [CI]: 0.55–1.12; $P = 0.177$) versus capecitabine 2,500 mg/m$^2$ [42]. There were also fewer cases with central nervous system involvement at progression in the combination group (4 vs. 13; $P = 0.045$).

A phase III study has investigated lapatinib 1,500 mg/day plus paclitaxel 175 mg/m$^2$ versus paclitaxel monotherapy for MBC first-line [43]. In the intent-to-treat population of 579 patients, no significant differences between groups were demonstrated for median duration of response (28 weeks
vs. 27 weeks) or TTP (29 weeks vs. 23 weeks). The ORR was 35% versus 25% ($P = 0.008$). In 86 HER2-positive patients (15%), paclitaxel plus lapatinib significantly improved TTP, event-free survival, ORR and clinical benefit rate compared with paclitaxel plus placebo. No significant differences between treatment groups were observed for any endpoint in HER2-negative patients.

Other lapatinib combinations with chemotherapy, hormonal therapy, or targeted agents are being tested. A phase II single-arm study (EGF105764) has evaluated lapatinib 1,500 mg/day and paclitaxel 80 mg/m$^2$ weekly every three weeks in 57 patients with newly diagnosed, HER2-positive MBC. The ORR was 51% and the median duration of response was 40 weeks [53]. Phase II trials of lapatinib plus vinorelbine (NCT00709618, NCT00754702) or nab-paclitaxel (NCT00709761) first- or second-line for MBC are recruiting. In a randomized trial of 1,286 postmenopausal women with hormone-receptor-positive untreated MBC from 212 international centers (EGF30008), patients received once-daily lapatinib 1,500 mg plus letrozole 2.5 mg versus letrozole alone [54]. In the HER2-positive population, median PFS significantly increased from 3.0 months in the letrozole group to 8.2 months in the lapatinib plus letrozole group ($P = 0.019$), and the ORR was 15% versus 28% ($P = 0.021$). In a phase II trial ($n = 52$), preliminary data for 32 patients receiving lapatinib 1,500 mg/day plus bevacizumab 10 mg/kg every two weeks has shown a crude 12-week PFS rate of 63% and an ORR of 13% [55]. The lapatinib plus trastuzumab combination is also under clinical investigation, as mentioned previously.

7. Ixabepilone and Targeted Therapy Combinations

The established antitumor activity of ixabepilone in MBC has prompted investigations of its efficacy combined with chemotherapy, or targeted therapies including trastuzumab, lapatinib, bevacizumab, and cetuximab. Preclinically, ixabepilone and trastuzumab have synergistic antitumor activity [56]. In a phase II trial of 39 patients with HER2-positive MBC, cohort 1 had received no prior chemotherapy or trastuzumab for MBC ($n = 15$) and cohort 2 had received one or two trastuzumab-containing regimens ($n = 24$). Both cohorts received ixabepilone 40 mg/m$^2$ every three weeks plus a trastuzumab 8 mg/kg loading dose on day 1 followed by 6 mg/kg every three weeks. The median age of patients was 51 and a median of seven cycles of therapy were administered in each cohort. Ixabepilone plus trastuzumab produced an ORR of 51% (clinical benefit rate 56%) and median age a median TTP of 6.1 months [57].

Phase II data indicate that ixabepilone, trastuzumab and carboplatin is active with acceptable toxicity first-line for HER2-positive MBC [58]. Of the 57 patients evaluated for response, two achieved a complete response (3.5%), 22 had partial response (38.6%) and 13 had stable disease extending beyond 6 months (22.8%). The median PFS was 8 months (95% CI: 6.0–9.7). Three phase II studies (ongoing or completed) combine trastuzumab and ixabepilone as first- or second-line therapy for HER2-positive advanced or MBC (NCT00490646, NCT00079326, NCT00337649).

Ixabepilone has antiangiogenic properties [59] and synergistic activity when used in combination with the antiangiogenic agents bevacizumab and sunitinib in a range of human tumor xenograft models, including breast [60,61]. Notably, the synergistic activity shown with ixabepilone was greater than with paclitaxel plus antiangiogenic agents, which may be, at least in part, attributable to the reduced susceptibility of ixabepilone for drug efflux pumps. A preliminary report illustrates that in combination with bevacizumab, both the weekly and every-3-week schedules of ixabepilone
demonstrated activity that was at least comparable to paclitaxel plus bevacizumab [62]. In addition, a randomized phase III trial is comparing paclitaxel to nab-paclitaxel or ixabepilone with all arms in combination with bevacizumab (CALGB 40452).

8. Combinations with PARP Inhibitors

Patients whose tumors are HER2-negative, particularly those with triple-negative disease, may experience significant benefits from members of a novel class of small molecules that inhibit poly(adenosine diphosphate-ribose) polymerase (PARP). PARP inhibitors block DNA damage repair, and their mechanism of action is thought to complement the DNA-damaging effects of platinum agents and antimetabolites [63]. One such compound, BSI-201, significantly improved the PFS (6.9 vs. 3.3; HR, 0.34 [0.20–0.58]; \( P < 0.0001 \)) and OS (9.2 vs. 5.7; HR, 0.35 [0.19–0.65]; \( P = 0.0005 \)) of gemcitabine and carboplatin in patients with triple-negative MBC in a recent randomized phase II study [63]. Another PARP inhibitor, olaparib, produced a 38% response rate in pretreated BRCA-deficient advanced breast cancer tumors [64].

9. Other Investigational Targeted Therapy Regimens

Several phase III studies of other regimens combining cytotoxic chemotherapy and targeted therapy are current or planned. Novel HER2 inhibitors beyond lapatinib are currently undergoing investigation in HER2-positive breast tumors, typically those which have progressed on or after trastuzumab therapy. Pertuzumab, which inhibits HER2 using a different mechanism than trastuzumab, has shown promise in combination with trastuzumab, even when disease has progressed on either agent alone [65]. Pertuzumab is also being evaluated in combination with trastuzumab and docetaxel first-line for MBC (NCT00567190). Likewise, in phase I/II trials, the pan-HER inhibitor neratinib has demonstrated clinical activity in combination with several chemotherapeutic agents, including paclitaxel [66], capecitabine [67], and vinorelbine [68].

Because mutations in the PI3-kinase/Akt pathway have been linked to trastuzumab resistance, researchers have pursued the downstream effector mammalian target of rapamycin (mTOR) in attempts to bypass such resistance. Dose-finding trials have revealed encouraging efficacy for the mTOR inhibitor everolimus (RAD001) in several trastuzumab-containing chemotherapy regimens, including those with paclitaxel [69], docetaxel [70], and vinorelbine [71], and in non-trastuzumab-containing combinations with capecitabine [72] and cisplatin/paclitaxel [73].

Sunitinib is an oral, small-molecule, receptor tyrosine kinase (RTK) inhibitor that is the current standard of care for renal cell carcinoma and gastrointestinal stromal tumor. Sunitinib inhibits cellular signaling by targeting multiple RTKs, including platelet-derived growth factor receptor (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R), which play a role in both tumor angiogenesis and tumor cell proliferation. In a phase II study of 64 patients with MBC pretreated with an anthracycline and a taxane, sunitinib was associated with an ORR of 11% [74]. Final results from a randomized phase II study (SABRE-B) showed that the addition of sunitinib to the approved paclitaxel plus bevacizumab regimen first-line was poorly tolerated, and the study was closed prematurely [75].
In addition, the results of the SUCON trial failed to demonstrate that sunitinib delays tumor progression following an objective response to taxane therapy [76].

In contrast, in patients with HER2-negative MBC, the multi-RTK inhibitor sorafenib showed promise in combination with capecitabine in the form of significantly improved PFS (6.4 months vs. 4.1 months; HR, 0.576 [0.410–0.809]) [77]. Sorafenib is now being combined with paclitaxel (NCT00499525), vinorelbine (NCT00764972), ixabepilone (NCT00825734), nab-paclitaxel (NCT00607438) and several hormonal therapies in ongoing phase II trials. The benefits of the anti-VEGFR2 monoclonal antibody IMC-1121B are also being explored in a phase III trial comparing single-agent docetaxel and docetaxel plus IMC-1121B in more than 1,100 patients with previously untreated HER2-negative MBC (NCT00703326).

9. Conclusions

In locally-advanced breast cancer and MBC, combination therapy with cytotoxic agents and targeted biologic agents has afforded significant clinical benefits in both first-line and salvage treatment settings, including improved tumor response and prolonged TTP compared with chemotherapy alone. This enhanced activity is largely attributable to additive or synergistic activity and generally nonoverlapping toxicity profiles for targeted and cytotoxic therapies. The results of numerous ongoing clinical trials combining cytotoxics and/or targeted biologic agents are awaited with interest, as it is anticipated that these will help to define the optimal role of various regimens in the management of MBC across multiple lines of therapy.

Acknowledgements

The author takes full responsibility for the content of this publication, and confirms that it reflects her viewpoint and medical expertise. She also wishes to acknowledge Helen Beaumont, DPhil, Laura Shepherd, PhD, and Rebecca Goldstein, PhD, from StemScientific, funded by Bristol-Myers Squibb, for providing writing and editing support for the literature research, preliminary draft, and collating author comments. Bristol-Myers Squibb did not influence the content of the manuscript, nor did the authors receive financial compensation for authoring the manuscript.

References and Notes

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M.J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58, 71–96.
2. Ries, L.A.G.; Melbert, D.; Krapcho, M.; Mariotto, A.; Miller, B.A.; Feuer, E.J.; Clegg, L.; Horner, M.J.; Howlader, N.; Eisner, M.P.; Reichman, M.; Edwards, B.K. SEER Cancer Statistics Review, 1975–2004. National Cancer Institute: Bethesda, MD, 2007. Available online at: http://seer.cancer.gov/statistics/ (accessed 4 August, 2009).
3. Sørlie, T.; Tibshirani, R.; Parker, J.; Hastie, T.; Marron, J.S.; Nobel, A.; Deng, S.; Johnsen, H.; Pesich, R.; Geisler, S.; Demeter, J.; Perou, C.M.; Lønning, P.E.; Brown, P.O.; Børresen-Dale,
A.L.; Botstein, D. Repeated observation of breast tumor subtypes in independent gene expression data sets. *Proc. Natl. Acad. Sci. USA* 2003, 100, 8418–8423.

4. Bafford, A.C.; Burstein, H.J.; Barkley, C.R.; Smith, B.L.; Lipsitz, S.; Iglehart, J. D.; Winer, E. P.; Golshan, M. Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. *Breast Cancer Res. Treat.* 2009, 115, 7–12.

5. National Comprehensive Cancer Network. Practice Guideline in Oncology – v.1.2009: Breast Cancer. Available online at: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf (accessed January 2009).

6. Cortazar, P.; Johnson, J.R.; Justice, R.; Pazdur, R. Metastatic breast cancer (MBC): FDA approval overview. *J. Clin. Oncol.* 2008, 26 (15S), Abstr. 1013.

7. Wang, Y.; Serradell, N.; Bolos, J.; Rosa, E. Eribulin mesilate. *Drugs Fut.* 2007, 32, 681.

8. Vahdat, L.T.; Twelves, C.; Ellison, M.K.; Cortes, J.A.; Campone, M.; Shuster, D.E.; Wanders, J.; Fang, F.; Gurnani, R.D.; Blum, J.L. Phase II study of eribulin mesylate (E7389) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracycline, taxane, and capecitabine therapy. *J. Clin. Oncol.* 2008, 26, Abstr. 1084.

9. Piccart-Gebhart, M.J.; Burzykowski, T; Buyse, M.; Sledge, G.; Carmichael, J.; Luck, H.J.; Mackey, J.R.; Nabholz, J.M.; Paridaens, R.; Biganzoli, L.; Jassim, J.; Bontenbal, M.; Bonneterre, J.; Chan, S.; Basaran, G.A.; Therasse, P. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. *J. Clin. Oncol.* 2008, 26, 1980–1986.

10. Albain, K.S.; Nag, S.M.; Calderillo-Ruiz, G.; Jordaan, J.P.; Llombart, A.C.; Pluzanska, A.; Rolski, J.; Melemed, A.S.; Reyes-Vidal, J.M.; Sekhon, J.S.; Simms, L.; O’Shaughnessy, J. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. *J. Clin. Oncol.* 2008, 26, 3950–3957.

11. Roy, V.; Laplant, B.R.; Gross, G.G.; Bane, C.L.; Palmieri, F.M.; North Central Cancer Treatment Group. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). *Ann. Oncol.* 2009, 20, 449–453.

12. Inoue, K.; Nakagami, K.; Mizutani, M.; Hozumi, Y.; Fugiwara, Y.; Masuda, N.; Tsukamoto, F.; Saito, M.; Miura, S.; Eguchi, K.; Shinkai, T.; Ando, M.; Watanabe, T.; Masuda, N.; Ohashi, Y.; Sano, M.; Noguchi, S. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. *Breast Cancer Res. Treat.* 2009, 119, 127–136.

13. Miller, K.; Wang, M.; Gralow, J.; Dickler, M.; Cobleigh, M.; Perez, E.A.; Shenkier, T.; Cella, D.; Davidson, N.E. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. *N. Engl. J. Med.* 2007, 357, 2666–2676.

14. Hurvitz, S.A.; Pegram, M.D.; Lin, L.S.; Chan, D.S.; Allen, H.J.; Dichmann, R.A.; Hagenstad, C.T.; Barstis, J.; Hermann, R.C.; Hu, E.H.; Moroose, R.L.; Thomas, S.P.; Vogel, C.L.; Ryba, N.; Elashoff, D.; Slamon, D.J. Final results of a phase II trial evaluating trastuzumab and bevacizumab as first-line treatment of HER2-amplified advanced breast cancer. Proceedings of the
San Antonio Breast Cancer Symposium, San Antonio, TX, USA, December 9–13, 2009; Abstr. 6094.

15. Helwick, C. Second-line bevacizumab plus chemo improves patient outcomes in metastatic disease. CancerNetwork.com. Available online at: http://www.cancernetwork.com/display/article/10165/1499062?CID=rss&verify=0 (Accessed December 15, 2009).

16. Blum, J.L.; Jones, S.E.; Buzdar, A.U.; LoRusso, P.M.; Kuter, I.; Vogel, C.; Osterwalder, B.; Burger, H.U.; Brown, C.S.; Griffin, T. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J. Clin. Oncol. 1999, 17, 485–493.

17. Blum, J.L.; Dieras, V.; LoRusso, P.M.; Horton, J.; Rutman, O.; Buzdar, A.; Osterwalder, B. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001, 92, 1759–1768.

18. O’Shaughnessy, J.; Miles, D; Vukelja, S.; Moiseyenko, V.; Ayoub, J.P.; Cervantes, G.; Fumoleau, P.; Jones, S.; Lui, W.Y.; Mauriac, L.; Twelves, C.; Van Hazel, G.; Verma, S.; Leonard, R. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J. Clin. Oncol. 2002, 20, 2812–2823.

19. Lee, F.Y.; Borzilleri, R.; Fairchild, C.R.; Kim, S.H.; Long, B.H.; Reventos-Suarez, C.; Vite, G.D.; Rose, W.C.; Kramer, R.A. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res. 2001, 7, 1429–1437.

20. Lee, F.Y.; Smykla, R.; Johnston, K.; Menard, K.; McGlinchey, K.; Peterson, R.W.; Wiebesiek, A.; Vite, G; Fairchild, C.R.; Kramer, R. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother. Pharmacol. 2009, 63, 201–212.

21. Goodin, S.; Kane, M.P.; Rubin, E.H. Epothilones: mechanism of action and biologic activity. J. Clin. Oncol. 2004, 22, 2015–2025.

22. Perez, E.A.; Lerzo, G.; Pivot, X.; Thomas, E.; Vahtat, L.; Bosserman, L.; Viens, P.; Cai, C.; Mullaney, B.; Peck, R.; Hortobagyi, G.N. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 2007, 25, 3407–3414.

23. Roché, H.; Yelle, L.; Cognetti, F.; Mauriac, L.; Bunnell, C.; Sparano, J.; Kerbrat, P.; Delord, J.P.; Vahtat, L.; Peck, R.; Lebwohl, D.; Ezzeddine, R.; Curé, H. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J. Clin. Oncol. 2007, 25, 3415–3420.

24. Thomas, E.S.; Gomez, H.L.; Li, R.K.; Chung, H.C.; Fein, L.E.; Chan, V.F.; Jassem, J.; Pivot, X.B.; Klimovisky, J.V.; de Mendoza, F.H.; Xu, B.; Campone, M.; Lerzo, G.L.; Peck, R.A.; Mukhopadhyay, P.; Vahtat, L.T.; Roché, H.H. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J. Clin. Oncol. 2007, 25, 5210–5217.

25. Thomas, E.S. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J. Clin. Oncol. 2008, 26, 2223.

26. Hortobagyi, G.N.; Perez, E.A.; Vrdoljak, E.; Medina, C.; Xu, B.; Conte, P.; Roche, H.; Peck, R.; Poulart, V.; Sparano, J.A. Analysis of overall survival (OS) among patients (pts) with metastastic
breast cancer (MBC) receiving either ixabepilone (I) plus capecitabine (C) or C alone: results from two randomized phase III trials. Proceedings of the American Society of Clinical Oncology (ASCO) Breast Cancer Symposium, Washington, DC, USA, September 5–7, 2008; Abstr. 186.

27. Roché, H.; Li, R.; Ro, J.; Vrdoljak, E.; Rahman, Z.U.; Medina, C.; Conte, P.; Volles, L.A.; Poulart, V.; Sparano, J.A. Ixabepilone plus capecitabine improves progression-free survival in patients with metastatic breast cancer resistant to taxanes: a pooled analysis from two phase III studies. Cancer Res. 2009, 69, Abstr. 2015.

28. Carey, L.A.; Dees, E.C.; Sawyer, L.; Gatti, L.; Moore, D.T.; Collichio, F.; Ollila, D.W.; Sartor, C.I.; Graham, M.L.; Perou, C.M. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 2007, 13, 2329–2334.

29. Rugo, H.S.; Roché, H.; Thomas, E.; Blackwell, K.; Chung, H.C.; Lerzo, G.; Volles, L.A.; Poulart, V.; Perez, E. Ixabepilone plus capecitabine vs. capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies. Cancer Res. 2009, 69, Abstr. 3057.

30. Lerzo, G.L.; Lee, R.K.; Thomas, E.S.; Chung, H.; Fein, L.E.; Chan, V.F.; Jassem, J.; Hurtado de Mendoza, F.; Mukhopadhyay, P.; Roché, H.H. Phase III study of ixabepilone plus capecitabine in metastatic breast cancer (MBC) progressing after anthracyclines and taxanes; Subgroup analysis in HER2+ disease. Proceedings of the American Society of Clinical Oncology (ASCO) Breast Cancer Symposium, San Francisco, CA, USA, September 7–8, 2007; Abstr. 151.

31. Pivot, X.B.; Lee, R.K.; Thomas, E.S.; Chung, H.; Fein, L.E.; Chan, V.F.; Jassem, J.; Hurtado de Mendoza, F.; Mukhopadhyay, P.; Roché, H.H. Phase III study of ixabepilone plus capecitabine in patients with metastatic breast cancer (MBC) resistant to anthracyclines/taxanes: Subgroup analysis by estrogen receptor (ER) status. Proceedings of the American Society of Clinical Oncology (ASCO) Breast Cancer Symposium, San Francisco, CA, USA, September 7–8, 2007; Abstr. 221.

32. Vahdat, L.; Fein, L.; Karwal, M.; Campone, M.; Peck, R.; Mukhopadhyay, P.; Jassem, J. Ixabepilone plus capecitabine in patients with metastatic breast cancer receiving ixabepilone in the first line setting: a pooled analysis from two phase II studies. Cancer Res. 2009, 69, Abstr. 6117.

33. Conte, P.; Roché, H.; Perez, E.A.; Sparano, J.; Xu, B.; Jassem, J.; Peck, R.; Mukhopadhyay, P.; Hortobagyi, G. Ixabepilone plus capecitabine improves overall survival in symptomatic patients with metastatic breast cancer previously treated with anthracycline and taxane in 2 large phase III studies. Cancer Res. 2009, 69, Abstr. 6114.

34. Roché, H.; Zambetti, M.; Dalenc, F.; Govi, S.; Gladieff, L.; Mudenda, B.; Lainas, I.; Iacono, L.; Gianni L. Phase Ib study of ixabepilone (I) in combination with epirubicin (E) in women with metastatic breast cancer. J. Clin. Oncol. 2008, 26 (15S), Abstr. 1058.

35. Miles, D.; Chan, A.; Romieu, G.; Dirix, L.Y.; Cortes, J.; Pivot, X.; Tomczak, P.; Taran, T.; Harbeck, N.; Steger, G.G. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J. Clin. Oncol. 2008, 26 (15S), Abstr. LBA1011.

36. Miller, K.D.; Chap, L.I.; Holmes, F.A.; Cobleigh, M.A.; Marcom, P.K.; Fehrenbacher, L.; Dickler, M.; Overmoyer, B.A.; Reimann, J.D.; Sing, A.P.; Langmuir, V.; Rugo, H.S.
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. *J. Clin. Oncol.* 2005, 23, 792–799.

37. Robert, N.J.; Dieras, V.; Glaspy, J.; Bruksky, A.; Bondarenko, I.; Lipatov, O.; Perez, E.; Yardley, D.; Zhou, X.; Phan, S. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). *J. Clin. Oncol.* 2009, 27 (15S), Abstr. 1005.

38. Slamon, D.J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N. Engl. J. Med.* 2001, 344, 783–792.

39. Robert, N.; Leyland-Jones, B.; Asmar, L.; Belt, R.; Ilegbodu, D.; Loesch, D.; Raju, R.; Valentine, E.; Sayre, R.; Cobleigh, M.; Albain, K.; McCullough, C.; Fuchs, L.; Slamon, D. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. *J. Clin. Oncol.* 2006, 24, 2786–2792.

40. Pegram, M.; Forbes, J.; Pienkowski, T.; Valero, V.; Eiermann, W.; Von Minckwitz, G.; Martin, M.; Crown, J.; Taupin, H.; Slamon, D. On behalf of the BCIRG007 investigators. BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). *J. Clin. Oncol.* 2007, 25 (18S), Abstr. LBA1008.

41. Von Minckwitz, G.; Zielinski, C.; Maartenese, E.; Vogel, P.; Schmidt, M.; Eitdmann, H.; Cufer, T.; de Jongh, F.E.; Kaufmann, M.; Loibl, S. Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3-05). *J. Clin. Oncol.* 2008, 26 (15S), Abstr. 1025.

42. Cameron, D.; Casey, M.; Press, M.; Lindquist, D.; Pienkowski, T.; Romieu, C.G.; Chan, S.; Jagiello-Gruszfeld, A.; Kaufman, B.; Crown, J.; Chan, A.; Campone, M.; Viens, P.; Davidson, N.; Gorbounova, V.; Raats, J.I.; Skarlos, D.; Newstact, B.; Roychowdhury, D.; Paoletti, P.; Oliva, C.; Rubin, S.; Stein, S.; Geyer, C.E. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. *Breast Cancer Res. Treat.* 2008, 112, 533–543.

43. Di-Leo, A.; Gomez, H.L.; Aziz, Z.; Zvirbule, Z.; Bines, J.; Arbushites, M.C; Guerrera, S.F.; Koehler, M.; Oliva, C.; Stein, S.H.; Williams, L.S.; Dering, J.; Finn, R.S.; Press, M.F. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. *J. Clin. Oncol.* 2008, 26, 5544–5552.

44. O'Shaughnessy, J.; Blackwell, K.L.; Burstein, H.; Storniolo, A.M.; Sledge, G.; Baselga, J.; Koehler, M.; Laabs, S.; Florance, A.; Roychowdhury, D. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. *J. Clin. Oncol.* 2008, 26 (15S), Abstr. 1015.

45. Link, J.S.; Wasiman, J.R.; Nguyen, B.; Jacobs, C.I. Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer. *Clin. Breast Cancer* 2007, 7, 779–783.
46. Lobo, C.; Lopes, G.; Silva, O.; Gluck, S. Paclitaxel albumin-bound particles (abraxane) in combination with bevacizumab with or without gemcitabine: early experience at the University of Miami/Braman Family Breast Cancer Institute. *Biomed. Pharmacother.* 2007, 61, 5321–5533.

47. Gluck, S.; Lobo, C.; Reis, I.; Lopes, G.; Carmody, C.; Tukia, K.; Hurley, J.; Seo, P.; Silva, O.; Slingerland, J.; Welsh, C. Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine for first-line therapy of patients with HER2-negative metastatic breast cancer (MBC). *J. Clin. Oncol.* 2008, 26 (15S), Abstr. 1089.

48. Sledge, G.; Miller, K.; Moisa, C.; Gradishar, W. Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer. *J. Clin. Oncol.* 2007, 25 (18S), Abstr. 1013.

49. Bonneterre, J.; Pion, J.M.; Adenis, A.; Tubiana-Hulin, M.; Tursz, T.; Marty, M.; Mathieu-Boué, A. A phase II study of a new camptothecin analogue CPT-11 in previously treated advanced breast cancer patients. *Proc. Am. Soc. Clin. Oncol.* 1993, 12, Abstr. 179.

50. Gasparini, G.; Gion, M.; Mariani, L.; Papaldo, P.; Crivellari, D.; Filippelli, G.; Morabito, A.; Silingardi, V.; Torino, F.; Spada, A.; Zancan, M.; De Sio, L.; Caputo, A.; Cognetti, F.; Lambiase, A.; Amadori, D. Randomized phase II trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. *Breast Cancer Res. Treat.* 2007, 101, 355–365.

51. Marty, M.; Cognetti, F.; Maraninchi, D.; Snyder, R.; Mauriac, L.; Tubiana-Hulin, M.; Chan, S.; Grimes, D.; Antón, A.; Lluch, A.; Kennedy, J.; O'Byrne, K.; Conte, P.; Green, M.; Ward, C.; Mayne, K.; Extra, J.M. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. *J. Clin. Oncol.* 2005, 23, 4265–4274.

52. Baselga, J.; Imadalou, K.; Paton, V.; Gray, D.; Swain, S. Efficacy, safety and tolerability of dual monoclonal antibody therapy with pertuzumab + trastuzumab in HER2+ metastatic breast cancer patients previously treated with trastuzumab. *Cancer Res.* 2009, 69, Abstr. 3138.

53. Jagiello-Gruszfeld, A.; Tjulandin, S.; Dobrovolskaya, N.; Manikhas, A.; Pienkowski, T.; Knott, A.; DeSilvio, M.; Oliva, C. Lapatinib (L) with weekly paclitaxel (P) as first-line therapy for patients (pts) with HER2+ metastatic breast cancer (MBC). *Cancer Res.* 2009, 69, Abstr. 3145.

54. Johnston, S.; Pegram, M.; Press, M.; Pippen, J.; Pivot, X.; Gomez, H.; Florance, H.; O'Rourke, L.; Maltzman, J. Lapatinib combined with letrozole vs. letrozole alone for front-line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 Trial. *Cancer Res.* 2009, 69, Abstr. 46.

55. Dickler, M.; Franco, S.; Stopeck, A.; Ma, W.; Nulsen, B.; Lyandres, J.; Melisko, M.; Lahiri, S.; Arbushites, M.; Koehler, M.; Rugo, H.S. Final results from a phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2-overexpressing metastatic breast cancer (MBC). *Cancer Res.* 2009, 69, Abstr. 3133.

56. Lee, F.Y.; Castaneda, S.; Inigo, I.; Kan, D.; Paul, B.; Wen, M.; Fairchild, C.; Clark, E.; Lee, H. Ixabepilone (BMS-247550) plus trastuzumab combination chemotherapy induces synergistic antitumour efficacy in HER 2 dependent breast cancers and is accompanied by modulation of molecular response markers. *J. Clin. Oncol.* 2005, 23 (16S), Abstr. 561.
57. Tolaney, S.M.; Najita, J.; Chen, W.; Savoie, J.; Fornier, M.; Krop, I.E.; Winer, E.P.; Bunnell, C. A phase II study of ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer. *Cancer Res.* **2009**, *69*, **3137**.

58. Moulder, S.L.; Wang, M.; Gradishar, W.; Perez, E.A.; Sparano, J.; Pins, M.; Sledge, G.; Eastern Cooperative Oncology Group. A phase II trial of trastuzumab, weekly ixabepilone and carboplatin (TIC) in patients with HER2/neu-positive (HER2+) metastatic breast cancer (MBC): A trial coordinated by the Eastern Cooperative Oncology Group (E2103). Proceedings of the American Society of Clinical Oncology (ASCO) Breast Cancer Symposium, San Francisco, CA, USA, September 7–8, 2007; *Abstr.* **152**.

59. IXEMPRA® Kit (ixabepilone) for injection [package insert]. Bristol-Myers Squibb Company: Princeton, NJ, USA, October 2009.

60. Covello, K.; McGlinchey, K.; Castaneda, S.; Kan, D.; Menard, K.; Lewin, A.; Wen, M.L.; Lee, F.Y. Ixabepilone is more cytotoxic than taxanes to proliferating endothelial cells and produced greater therapeutic synergism in combination with antiangiogenic therapy. *Proc. Am. Assoc. Cancer Res.* **2007**, *48*, **5738**.

61. Lee, F.Y.; Castenada, S.; Hawken, D.; Hickey, C.; Kan, D.; Lewin, A.; Wen, M.-L.; Ryseck, R.; Fargnoli, J.; Kramer, R. Bevacizumab/ixabepilone (BMS-247550) combination produces synergistic antitumor efficacy in multiple tumor models in vivo and is superior to bevacizumab/paclitaxel combination. Proceedings of the AACC-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Philadelphia, PA, USA, November 14–18, 2005; *Abstr.* **B246**.

62. Rugo, H.S.; Campone, M.; Amadori, D.; Wardley, A.; Villa, E.; Conte, P. F.; Mudenda, B.; McHenry, B.; Pivot, X. Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC). *J. Clin. Oncol.* **2009**, *27*(15S), **1029**.

63. O'Shaughnessy, J.; Osborne, C.; Pippen, J.; Patt, D.; Rocha, C.; Ossovskaya, V.; Sherman, B.; Bradley, C. Final results of a randomized phase II study demonstrating efficacy and safety of BSI-201, a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with gemcitabine/carboplatin (G/C) in metastatic triple negative breast cancer (TNBC). Proceedings of the San Antonio Breast Cancer Symposium, San Antonio, TX, USA, December 9–13, 2009; *Abstr.* **3122**.

64. Tutt, A.; Robson, M.; Garber, J.E.; Domchek, S.; Audeh, M.W.; Weitzel, J.N.; Friedlander, M.; Carmichael, J. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. *J. Clin. Oncol.* **2009**, *27*(15S), **CRA501**.

65. Baselga, J.; Cortes, J.; Fumoleau, P.; Petrella, T.; Gelmon, K.; Verma, S.; Pivot, X.; Ross, G.; Szado, T.; Gianni, L. Pertuzumab and trastuzumab: re-responses to 2 biological agents in patients with HER2-positive breast cancer which had previously progressed during therapy with each agent given separately: a new biological and clinical observation. Proceedings of the San Antonio Breast Cancer Symposium, San Antonio, TX, USA, December 9–13, 2009; *Abstr.* **5114**.

66. Chow, L.; Gupta, S.; Hershman, D.; Jiang, Z.; Epstein, R.; Bondarenko, I.; Coughlin, C.; Freyman, A.; Zhou, Y.; Abbas, R.; Awada, A. Safety and efficacy of neratinib (HKI-272) in
combination with paclitaxel in ErbB2+ metastatic breast cancer. Proceedings of the San Antonio Breast Cancer Symposium, San Antonio, TX, USA, December 9–13, 2009; Abstr. 5081.

67. Saura, C.; Martin, M.; Moroose, R.; Harb, W.; Liem, K.; Arena, F.; Gressler, V.; Cortés, J.; Wade, M.; Powell, C.; Shapiro, M. Safety and efficacy of neratinib (HKI-272) in combination with capecitabine in patients with solid tumors: a phase 1/2 study. Proceedings of the San Antonio Breast Cancer Symposium, San Antonio, TX, USA, December 9–13, 2009; Abstr. 5108.

68. Awada, A.; Dirix, L.; Beck, J.; Luu, T.; Dieras, V.; Llombart, A.; Manso, L.; Limentani, S.; Binlich, F.; Germa, C.; Abbas, R.; Agrapart, V.; Powell, C.; Hershman, D. Safety and efficacy of neratinib (HKI-272) in combination with vinorelbine in ErbB2+ metastatic breast cancer. Proceedings of the San Antonio Breast Cancer Symposium, San Antonio, TX, USA, December 9–13, 2009; Abstr. 5095.

69. Campone, M.; O’Regan, R.; Hurvitz, S.; Naughton, M.; Manlius, C.; Vittori, L.; Mukhopadhyay, P.; Massacesi, C.; Sahmoud, T.; André, F. Everolimus plus weekly paclitaxel and trastuzumab in patients (pts) with HER2+ metastatic breast cancer (MBC) with prior resistance to trastuzumab: a phase I clinical trial. Proceedings of the American Society of Clinical Oncology (ASCO) Breast Cancer Symposium, San Francisco, CA, USA, Oct 8–10, 2009; Abstr. 218.

70. Moulder, S.L.; Rivera, E.; Ensor, J.; Gonzalez-Angulo, A.; Cristofanilli, M.; Booser, D.; Giordano, S.; Brewster, A.; Hortobagyi, G.; Tran, H. Phase I trial of escalating doses of weekly everolimus (RAD001) in combination with docetaxel for the treatment of metastatic breast cancer (MBC). J. Clin. Oncol. 2009, 27 (15S), Abstr. 1066.

71. Dieras, V.; Gianni, L.; Jerusalem, G.; Fasolo, A.; Cardoso, F.; Vittori, L.; Mukhopadhyay, P.; Massacesi, C.; Sahmoud, T.; Bergh, J. Phase I clinical trial of everolimus (E) in combination with vinorelbine (V) and trastuzumab (H) in patients with HER-2-positive (HER2+) metastatic breast cancer (MBC) with prior resistance to trastuzumab. Proceedings of the American Society of Clinical Oncology (ASCO) Breast Cancer Symposium, San Francisco, CA, USA, Oct 8–10, 2009; Abstr. 253.

72. Chen, C.S.; Chen, M.M.; Imaoka, R.T.; Svahn, T.; Guardino, A.E. A phase I pilot study of the oral mTOR inhibitor RAD001 in combination with capecitabine for metastatic breast cancer. Proceedings of the San Antonio Breast Cancer Symposium, San Antonio, TX, USA, December 9–13, 2009; Abstr. 6112.

73. Mayer, I.A.; Burris, H.A.; Bendell, J.C.; Means-Powell, J.; Arteaga, C.L.; Shyr, Y.; Pietenpol, J.A. A phase Ib trial of RAD001, an mTOR inhibitor, with weekly cisplatin and paclitaxel in patients with HER2-negative metastatic breast cancer. Proceedings of the San Antonio Breast Cancer Symposium, San Antonio, TX, USA, December 9–13, 2009; Abstr. 3093.

74. Burstein, H.J.; Elias, A.D.; Rugo, H.S.; Cobleigh, M.A.; Wolff, A.C.; Eisenberg, P.D.; Lehman, M.; Adams, B.J.; Bello, C.L.; DePrimo, S.E.; Baum, C.M.; Miller, K.D. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 2008, 26, 1810–1816.

75. Mayer, E.; Kozloff, M.; Qamar, R.; Klencke, B.; Balkissoon, J.; Parmar, H.; Samant, M.; Burstein, H.J. SABRE-B: a randomized phase II trial evaluating the safety and efficacy of
combining sunitinib (S) with paclitaxel (P) + bevacizumab (B) as first-line treatment for HER2-negative metastatic breast cancer (MBC): final results. *Cancer Res.* **2009**, *69*, Abstr. 3126.

76. Wildiers, H.; Fontaine, C.; Vuylsteke, P.; Martens, M.; Canon, J.-L.; Wynendaele, W.; Focan, C.; Degreve, J.; Paridaens, R. SUCON trial (SUnitinib CONsolidation Therapy in Metastatic Breast Cancer): A Belgian multicenter phase II randomized trial in HER2-negative metastatic breast cancer evaluating consolidation antiangiogenic therapy with sunitinib after objective response to taxane chemotherapy. Proceedings of the San Antonio Breast Cancer Symposium, San Antonio, TX, USA, December 9–13, 2009; Abstr. 203.

77. Baselga, J.; Segalla, J.G.M.; Roché, H.; del Giglio, A.; Ciruelos, E.M.; Cabral-Filho, S.; Gomez, P.; Lluch, A.; Llombart, A.; Costa, F. SOLTI-0701: a double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with capecitabine (CAP) in patients (pts) with locally advanced (adv) breast cancer (BC). Proceedings of the Joint European Cancer Organisation/European Society of Medical Oncology Multidisciplinary Congress, Berlin, Germany, September 20–24, 2009; Abstr. 3LBA.

© 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).